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INTRODUCTION
The advent of the molecular imaging era has offered to pharmacologists very powerful tools for
drug discovery and development, in vivo evaluation of pharmacokinetic properties, andmonitoring
drug efficacy (Hargreaves, 2008; Nairne et al., 2015). In fact, molecular imaging technologies
provide minimally invasive procedures to visualize, characterize, and quantify biological processes
occurring at cellular/subcellular level (Weissleder and Mahmood, 2001), thus overcoming the poor
clinical translatability often exhibited by in vitro/ex-vivo experimental models.
The continuous advances in biomedical imaging technologies may significantly boost the
development of novel and more effective drugs, and accelerating the selection of lead compounds,
with important time and costs benefits for healthcare.
In vivo imaging of drug delivery and release, as well as monitoring of the therapeutic outcomes,
represent the base of personalized medicine, thus allowing patients to be successfully addressed to
the more effective therapeutic regime.
Overall, the use of molecular imaging procedures aimed at supporting any therapeutic
intervention (including surgery) falls within the scopes of theranosis (Lammers et al., 2011).
Focusing on pharmacological therapies, a typical theranostic procedure requires the design of
an imaging-traceable agent, whose structure and properties are suitably tailored to the aims of
the examination. Imaging drug-delivery allows the assessment of the accumulation of the drug
at the biological target, thus helping the selection of the more appropriate treatment. To get
accurate information, the imaging agent should have the same physico-chemical properties of the
drug. This requirement can be successfully met by labeling pharmaceuticals (organic molecules,
peptides, proteins, radiochelates) with PET- or SPECT-traceable radioisotopes, because of the
minimal structural perturbation caused by the introduction of commonly used radionuclides (e.g.,
18F, 11C, 123I, 68Ga, 111In; Baum et al., 2010; Gains et al., 2011; Gomes et al., 2011; Witzig et al.,
2013; Wynendaele et al., 2014).
On the other hand, when the drug is loaded into a nanocarrier, also the other available imaging
modalities (CT, MRI, NIRF, US, PAI) can be used to visualize the delivery of the pharmaceutical.
The imaging probe can be loaded in the carrier alone or together with the drug. The first option
is preferable for drug selection, the second one for monitoring therapies. Among the imaging
technologies, MRI is an excellent choice because combines exquisite spatial resolution, no limits
in tissue penetration, and a vast portfolio of probes and contrast modalities that allows the
design/selection of the best agent for any theranostic application.
CLASSIFICATION OF MRI CONTRAST AGENTS
MRI contrast agents can be grouped in five classes: T1 agents, T2/T2
∗ agents, CEST agents,
19F-based agents, and hyperpolarized probes (Figure 1).
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FIGURE 1 | Main classes of MRI Contrast Agents in pharmacological
research.
This section intends to provide the reader a brief description
of these systems focusing on their main pro and cons with
particular reference to the applications in pharmacological
research.
T1 AGENTS
T1 agents are mostly represented by paramagnetic metal [Gd(III)
or Mn(II)] complexes that enhance the MR water signal (signal
brightening) in T1w scans. The main benefits using T1 agents
relies on the high versatility of this contrast mechanism that is
affected by a large number of factors related to either structural
and dynamic characteristics of the agent or biological aspects
like the intra-voxel distribution of the probe (e.g., intra/extra-
vascular, intra/extra-cellular). A representative example is the
use of paramagnetic complexes to visualize the delivery and
the release of a drug from liposomes (Viglianti et al., 2006;
Hijnen et al., 2014; Rizzitelli et al., 2015). However, such
systems displayed a limited sensitivity that makes necessary
a local concentration of agent around 10µM. This drawback
can be partially overcome using nanometric materials that
can aggregate even millions of contrastographic units, thus
reducing significantly the local concentration of contrast agent





∗ agents are chemicals, mostly superparamagnetic
nanoparticles made of iron oxides, capable to shorten the T2/T2
∗
of water protons much more than T1. Thus, their presence in
the MRI image is signaled by a signal loss (darkening). Such
nanoparticles show an intrinsic higher sensitivity than T1 agents
that justifies their extensive use in MR-molecular imaging
procedures, especially for cellular imaging (Srivastava et al.,
2015). On the other side, these agents are often considered not to
be the candidates of choice for designing smart agents, due to the
difficulty to modulate the T2/T2
∗ contrast as a function of the
microenvironment characteristics. Furthermore, the signal loss
is not desirable when the target site has an intrinsically low signal
(e.g., lungs, hemorrhages). However, interesting and promising
theranostic applications of iron oxide nanoparticles for the
visualization of drug delivery and release have been recently
published (Krol et al., 2013; Liu et al., 2013).
CEST AGENTS
The family of CEST agents is constantly growing, and though
there are no agents in clinical trials yet, the peculiarities of these
systems could open new and interesting future perspectives for
MRI agents in pharmacology research. The acronymCEST stands
for Chemical Exchange Saturation Transfer and identifies those
chemicals that generate a MRI contrast through the transfer,
mediated by chemical exchange, of saturated (i.e., irradiated with
a frequency specific RF pulse) protons from the donor pool
(CEST agent) to the acceptor pool (bulk water).
The most important advantage of using CEST agents is that
the contrast can be detected only following the irradiation of the
specific NMR resonance of the donor pool. It follows that the
detection of the agent is frequency-encoded and this property
can be exploited for multiplex imaging or for the design of
concentration-independent smart agents, both tasks being very
challenging in the case of the above described relaxation agents.
The sensitivity of CEST contrast detection was recognized as
an issue since the early days of the development of these agents
(Ward et al., 2000). Few mM of the donor pool are necessary.
However, in analogy with T1 agents, a large sensitivity gain
can be accomplished by recurring to nanosystems. As far as
the use of CEST agents in pharmacology, excellent results have
been obtained using liposomes as carriers of a huge amount
of exchanging water protons (the water molecules entrapped
in the nanovesicles) properly shifted by the entrapment of a
paramagnetic shift reagent in the inner aqueous compartment.
The resulting systems (called LipoCEST, Aime et al., 2005) have
been demonstrated to be very promising for imaging drug release
at preclinical level (Langereis et al., 2009; Delli Castelli et al., 2010;
Castelli et al., 2014).
HETERONUCLEAR AGENTS
CEST agents share the frequency-encoded contrast property
with agents containing MRI detectable nuclei different from
protons. Among them, two classes deserve to be mentioned here
because there are compounds already approved for humans or in
advanced clinical trials: 19F agents and hyperpolarized probes.
19F AGENTS
19F nuclei are the most sensitive spins after protons, and,
therefore can be detected by MRI without any enrichment. The
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detection sensitivity is similar to CEST agents (few mM of
fluorine atoms). Consequently, 19F agents are almost exclusively
represented by nanosystems, among which perfluorocarbon
nanoparticles (PFCs) are by far the most commonly used (Jacoby
et al., 2013). The important advantage of fluorinated agents over
the other class of contrast media stems from the possibility
to directly correlate the MR signal to the agent concentration,
thus allowing the quantification of targeted biomarkers and/or
drugs delivered at the site of interest (Lanza et al., 2002). A
commercially available formulation of PFCs will enter soon in
clinical phase 1 for labeling and in vivo tracking human adipose-
derived stem cells for breast reconstruction [19F Hot Spot MRI
of Human Adipose-derived Stem Cells for Breast Reconstruction
(CS-1000), ID NCT02035085, source: ClinicalTrials.gov].
HYPERPOLARIZED PROBES
This class of MRI agents is by far the most sensitive one,
owing to the use of polarization techniques (like dynamic
nuclear polarization, DNP, laser optical pumping, para-hydrogen
induced polarization) that increase dramatically (up to five order
of magnitude) the population difference between the spin energy
levels. These agents have some similarity with PET tracer, not
only for the excellent sensitivity, but also for the decay of the
signal they generate (caused by the return back to the thermal
polarization) that occurs on the timescale of the T1 of the
polarized spin. Hence, one limitation in the use of hyperpolarized
probes is the signal loss over time that requires fast injection and
rapid accumulation at the target site.
Hyperpolarized gases (e.g., 3He and 129Xe) are clinically
used for imaging the respiratory apparatus (Liu et al., 2014),
whereas a 13C hyperpolarized compound (13C pyruvate)
is currently in phase 1 clinical trial as metabolic agents
for prostate cancer diagnosis (University of California,
2010). Besides cancer, 13C hyperpolarized agents are under
intense scrutiny in cardiovascular research (Rider and Tyler,
2013).
The use of hyperpolarized probes for imaging drug delivery
is quite limited, mainly due to the time constrain. Hence, their
impact in pharmacological research is primarily in monitoring
therapy outcome (Laustsen et al., 2014; Park et al., 2014).
A very intriguing combination between hyperpolarized and
CEST agents has been proposed using 129Xe-based probes. The
contrast arising from these agents (dubbed Hyper-CEST) relies
on the reversible binding of hyperpolarized Xe with amacrocyclic
host (e.g., cryptophane, cucurbituril; Schröder et al., 2006). The
large chemical shift difference between the exchanging free and
host-bound species allows the generation of a CEST contrast
where the presence of very small amounts of the host-bound
Xe can be detected after transferring its saturation to the signal
of the free gas. In vitro proof-of-concepts highlighting the great
potential and high sensitivity of these agents has been very
recently published (Kunth et al., 2015; Schnurr et al., 2015).
CONCLUSIONS
In spite of the intrinsic limited sensitivity of NMR/MRI response,
several routes have been identified to allow the use of MRI probes
in pharmacological studies. The enhanced sensitivity allows to
take advantage of the superb spatial and temporal resolution of
the MR imaging modality. On this basis, MRI is increasing its
competitiveness in the Molecular Imaging arena, allowing the
design of innovative experiments that provide a detailed picture
of the biological microenvironment at cellular and molecular
level. Moreover, functional and molecular MRI investigations
imply a level of invasiveness that is definitively low in respect to
the commonly used probes for nuclear medicine.
Finally, the use of frequency-encoding agents opens new
horizons as they allow the visualization of more targets in the
same anatomical region, i.e., they provide the access tomulticolor
MR images of the kind the biomedical operators are used to deal
with in the histological characterization of bioptical specimens.
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